Euroasian journal of hepato-gastroenterology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  14 (2024)
Volume  13 (2023)
Volume  12 (2022)
Volume  11 (2021)
Volume  10 (2020)
Volume  9 (2019)
Volume  8 (2018)
Volume  7 (2017)
Volume  6 (2016)
Volume  5 (2015)
Volume  4 (2014)
Volume  3 (2013)
Volume  2 (2012)
Volume  1 (2011)
Related articles

VOLUME 14 , ISSUE 2 ( July-December, 2024 ) > List of Articles

CASE REPORT

Complete Response with Immunotherapy Alone after Discontinuing VEGF Inhibitor in Advanced Hepatocellular Carcinoma: A Case Report

Mohammad SS Naviwala, Daania Shoaib, Waqas A Khan, Adeeba Zaki

Keywords : Atezolizumab, Bevacizumab, Case report, Complete response, Hepatocellular carcinoma, Hypertension, Spinal decompression, Progression-free survival, Proteinuria

Citation Information : Naviwala MS, Shoaib D, Khan WA, Zaki A. Complete Response with Immunotherapy Alone after Discontinuing VEGF Inhibitor in Advanced Hepatocellular Carcinoma: A Case Report. Euroasian J Hepatogastroenterol 2024; 14 (2):246-250.

DOI: 10.5005/jp-journals-10018-1455

License: CC BY-NC 4.0

Published Online: 27-12-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Bevacizumab and atezolizumab combination is one of the preferred combinations for managing advanced hepatocellular carcinoma (HCC), while the evidence on monotherapy with either agent is not convincing. We present a case of a man in his 50s diagnosed with HCC with spinal metastases who showed a good response to combination therapy. However, he developed severe proteinuria and hypertension secondary to bevacizumab, which had to be discontinued after 18 cycles. After an informed decision, atezolizumab was continued and the patient showed a sustained response. Till date, he has received 16 additional cycles of atezolizumab monotherapy after discontinuation of bevacizumab and continues to show a persistent response, with a progression-free survival of over 30 months now. It needs to be prospectively evaluated if atezolizumab's effectiveness as monotherapy for extended periods, as in our report, is a residual effect of initial combination therapy or if HCC is intrinsically responsive to immunotherapy alone.

PDF Share
  1. Fenton SE, Burns MC, Kalyan A. Epidemiology, mutational landscape and staging of hepatocellular carcinoma. Chin Clin Oncol 2021;10(1):2. DOI: 10.21037/cco-20-162.
  2. Dasgupta P, Henshaw C, Youlden DR, et al. Global trends in incidence rates of primary adult liver cancers: A systematic review and meta-analysis. Frontiers in Oncology 2020;10:171. DOI: 10.3389/fonc.2020.00171.
  3. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66(2):115–132. DOI: 10.3322/caac.21338.
  4. Sayiner M, Golabi P, Younossi ZM. Disease burden of hepatocellular carcinoma: A Global perspective. Dig Dis Sci 2019;64(4):910–917. DOI: 10.1007/s10620-019-05537-2.
  5. Kim HS, El-Serag HB. The epidemiology of hepatocellular carcinoma in the USA. Curr Gastroenterol Rep 2019;21(4):17. DOI: 10.1007/s11894-019-0681-x.
  6. Cucchetti A, Cescon M, Trevisani F, et al. Current concepts in hepatic resection for hepatocellular carcinoma in cirrhotic patients. World J Gastroenterol 2012;18(44):6398–6408. DOI: 10.3748/wjg.v18.i44.6398.
  7. Colagrande S, Inghilesi AL, Aburas S, et al. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol 2016;22(34):7645–7659. DOI: 10.3748/wjg.v22.i34.7645.
  8. Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2022;76(4):862–873. DOI: 10.1016/j.jhep.2021.11.030.
  9. Los M, Roodhart JML, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 2007;12(4):443–450. DOI: 10.1634/theoncologist.12-4-443.
  10. Syn NL, Teng MWL, Mok TSK, et al. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol 2017;18(12):e731–e741. DOI: 10.1016/S1470-2045(17)30607-1.
  11. Wallin JJ, Bendell JC, Funke R, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun 2016;7:12624. DOI: 10.1038/ncomms12624.
  12. Zhu X, Wu S, Dahut WL, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis. Am J Kidney Dis 2007;49(2):186–193. DOI: 10.1053/j.ajkd.2006.11.039.
  13. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358(11):1129–1136. DOI: 10.1056/NEJMoa0707330.
  14. Frangié C, Lefaucheur C, Medioni J, et al. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007;8(2):177–178. DOI: 10.1016/S1470-2045(07)70037-2.
  15. Perazella MA, Izzedine H. New drug toxicities in the onco-nephrology world. Kidney Int 2015;87(5):909–917. DOI: 10.1038/ki.2015.30.
  16. Oura K, Morishita A, Tani J, et al. Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: A Review. Int J Mol Sci 2021;22(11):5801. DOI: 10.3390/ijms22115801.
  17. Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 2022;19(3):151–172. DOI: 10.1038/s41571-021-00573-2.
  18. Kudo M. Scientific rationale for combined immunotherapy with PD-1/PD-L1 Antibodies and VEGF inhibitors in advanced hepatocellular carcinoma. Cancers (Basel) 2020;12(5):1089. DOI: 10.3390/cancers12051089.
  19. Sangro B, Sarobe P, Hervás-Stubbs S, et al. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18(8):525–543. DOI: 10.1038/s41575-021-00438-0.
  20. Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2022;23(1):77–90. DOI: 10.1016/S1470-2045(21)00604-5.
  21. Leowattana W, Leowattana T, Leowattana P. Systemic treatment for unresectable hepatocellular carcinoma. World J Gastroenterol 2023;29(10):1551–1568. DOI: 10.3748/wjg.v29.i10.1551.
  22. Rimassa L, Personeni N, Czauderna C, et al. Systemic treatment of HCC in special populations. J Hepatol 2021;74(4):931–943. DOI: 10.1016/j.jhep.2020.11.026.
  23. Wu S, Kim C, Baer L, et al. Bevacizumab increases risk for severe proteinuria in Cancer patients. J Am Soc Nephrol 2010;21(8):1381–1389. DOI: 10.1681/ASN.2010020167.
  24. Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 2010;46(2):439–448. DOI: 10.1016/j.ejca.2009.11.001.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.